Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 1
1967 1
1968 6
1969 3
1970 2
1971 7
1972 18
1973 22
1974 22
1975 51
1976 66
1977 66
1978 68
1979 66
1980 43
1981 81
1982 88
1983 74
1984 95
1985 97
1986 98
1987 94
1988 88
1989 112
1990 116
1991 150
1992 137
1993 136
1994 149
1995 154
1996 136
1997 135
1998 155
1999 110
2000 117
2001 106
2002 129
2003 120
2004 116
2005 113
2006 123
2007 123
2008 104
2009 105
2010 128
2011 109
2012 124
2013 101
2014 106
2015 111
2016 93
2017 88
2018 106
2019 78
2020 81
2021 78
2022 47
2023 50
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

4,821 results

Results by year

Filters applied: . Clear all
Page 1
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Bartlett NL, et al. J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2. J Clin Oncol. 2019. PMID: 30939090 Free PMC article. Clinical Trial.
PURPOSE: Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and …
PURPOSE: Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine …
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, Chisholm JC. Defachelles AS, et al. J Clin Oncol. 2021 Sep 20;39(27):2979-2990. doi: 10.1200/JCO.21.00124. Epub 2021 Aug 3. J Clin Oncol. 2021. PMID: 34343032 Clinical Trial.
PURPOSE: The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS). METHODS: In this randomized European phase II tria …
PURPOSE: The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without …
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Arndt CA, et al. J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770373 Free PMC article. Clinical Trial.
PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincris …
PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standar …
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Kantarjian H, et al. Cancer. 2004 Dec 15;101(12):2788-801. doi: 10.1002/cncr.20668. Cancer. 2004. PMID: 15481055 Free article. Clinical Trial.
The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) program, with a median follow-up time of 63 months. ...
The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, an …
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.
Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Leavey PJ, et al. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. doi: 10.1200/JCO.21.00358. Epub 2021 Oct 15. J Clin Oncol. 2021. PMID: 34652968 Free PMC article. Clinical Trial.
PURPOSE: The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarc …
PURPOSE: The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophos …
Prospective clinical trial to compare vincristine and vinblastine in a COP-based protocol for lymphoma in cats.
Krick EL, Cohen RB, Gregor TP, Salah PC, Sorenmo KU. Krick EL, et al. J Vet Intern Med. 2013 Jan-Feb;27(1):134-40. doi: 10.1111/jvim.12006. Epub 2012 Nov 17. J Vet Intern Med. 2013. PMID: 23157371 Free article. Clinical Trial.
HYPOTHESIS/OBJECTIVES: The study purpose was to compare response rate, outcome, and toxicity between cats that received vincristine or vinblastine as part of combination chemotherapy for lymphoma. We hypothesized that vinblastine would have similar efficacy, but less gastr …
HYPOTHESIS/OBJECTIVES: The study purpose was to compare response rate, outcome, and toxicity between cats that received vincristine o …
Comparison of efficacy and safety of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma: A multicenter prospective randomized controlled clinical trial.
Yao W, Li K, Wang Z, Wang J, Ji Y, Zhou L, Huang H, Gao X, Huang Z, Gu S, Yang H, Zheng S. Yao W, et al. J Dermatol. 2021 May;48(5):576-584. doi: 10.1111/1346-8138.15767. Epub 2021 Feb 19. J Dermatol. 2021. PMID: 33608936 Clinical Trial.
The purpose of this multicenter prospective randomized controlled study was to evaluate and compare the efficacy of corticosteroid and vincristine (VCR) in the treatment of KHE and TA. All patients with KHE/TA who met the diagnostic criteria were consecutively recruited. . …
The purpose of this multicenter prospective randomized controlled study was to evaluate and compare the efficacy of corticosteroid and vi …
Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Xu J, Xie L, Sun X, Liu K, Liang X, Cai Z, Tang X, Guo W. Xu J, et al. Clin Cancer Res. 2023 Mar 14;29(6):1040-1046. doi: 10.1158/1078-0432.CCR-22-3546. Clin Cancer Res. 2023. PMID: 36622702 Clinical Trial.
PURPOSE: The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification. PATIENTS AND METHODS: Patients with relapsed or refractory Ewing sarcoma were randomly assigned (1:1) to eith …
PURPOSE: The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing s …
High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.
Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D. Schiller GJ, et al. J Adolesc Young Adult Oncol. 2018 Oct;7(5):546-552. doi: 10.1089/jayao.2018.0041. Epub 2018 Sep 21. J Adolesc Young Adult Oncol. 2018. PMID: 30239252 Clinical Trial.
PURPOSE: A study of vincristine sulfate (VCR) liposome injection (VSLI) was conducted in patients with advanced, relapsed, or refractory, Philadelphia chromosome-negative acute lymphoblastic/lymphocytic leukemia (ALL). ...
PURPOSE: A study of vincristine sulfate (VCR) liposome injection (VSLI) was conducted in patients with advanced, relapsed, or refract …
Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
Xu J, Xie L, Sun X, Liu K, Tang X, Yan T, Yang R, Guo W, Gu J. Xu J, et al. Oncologist. 2021 Jul;26(7):e1256-e1262. doi: 10.1002/onco.13726. Epub 2021 Mar 8. Oncologist. 2021. PMID: 33611805 Free PMC article. Clinical Trial.
The most frequently observed grade 3/4 adverse events were leukopenia (28.5%), neutropenia (24.4%), anemia (8.7%), and diarrhea (3.7%). CONCLUSION: The combination of vincristine, irinotecan, and anlotinib demonstrated an acceptable toxicity profile and promising clinical …
The most frequently observed grade 3/4 adverse events were leukopenia (28.5%), neutropenia (24.4%), anemia (8.7%), and diarrhea (3.7%). CONC …
4,821 results